Clinical Trials on Solid Malignancy

Total 9481 results

City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Perception of Cure Among Patients With Metastatic Cancer

Hematopoietic and Lymphoid Cell Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Xiaoyan Zhang

Completed

Clinical Research on Comprehensive Treatment of Tuberculosis With Malignant Solid Tumor

Malignant Solid Tumor

China
Puma Biotechnology, Inc.

Completed

A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer

Breast Neoplasms | Advanced Breast Cancer | Advanced Malignant Solid Tumors

United States, Belgium, China, Hong Kong, Canada, Korea, Republic of, India, Poland, Ukraine
Robert Wesolowski

Completed

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors

Breast Cancer | Ovarian Cancer | Malignant Solid Tumour | GIST | Malignant Tumor of Colon

United States
Aurigene Discovery Technologies Limited

Recruiting

A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)

Relapsed Malignant Solid Neoplasm

India
University Hospital Tuebingen

Active, not recruiting

Immunity to Infection in Healthy Participants and Participants With Cancer (SYS01)

Solid Tumor | Influenza | SARS-CoV-2 | Hematologic Malignancy

Germany
Incyte Corporation

Terminated

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Solid Tumors and Hematologic Malignancy

United States, Netherlands, Belgium
Sidney Kimmel Comprehensive Cancer Center at Johns...
Johns Hopkins University; Axogen Corporation

Completed

Non-Invasive Neurosensory Testing For Chemotherapy-Induced Peripheral Neuropathy

Cancer | Neuropathy | Malignant Neoplasm | Chemotherapy-induced Peripheral Neuropathy | Malignancy | Neuropathies Sensory

United States
National Cancer Institute (NCI)

Active, not recruiting

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Glioblastoma | WHO Grade 3 Glioma | Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Glioma | Recurrent Cholangiocarcinoma | WHO Grade 2 Glioma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
National Cancer Institute (NCI)

Recruiting

Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Brain

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Dual Time Point FDG PET/MRI Scan in Improving the Imaging Cancer Patients With Brain Metastases

Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Brain

United States
National Cancer Institute (NCI)

Active, not recruiting

Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors

Cirrhosis | Hepatitis B Infection | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm | Recurrent Hepatocellular Carcinoma | Refractory Malignant Neoplasm | Hepatitis C Infection | Stage IV Hepatocellular Carcinoma AJCC v7

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Ipilimumab and Imatinib Mesylate in Advanced Cancer

Metastatic Melanoma | Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Melanoma | C-KIT Tyrosine Kinase Protein Overexpression | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Gastrointestinal Stromal Tumor | Pathologic Stage IV Cutaneous Melanoma... and other conditions

United States
Emory University
National Cancer Institute (NCI)

Active, not recruiting

Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
Peking University

Recruiting

A Clinical Study on Evaluating Intravenous Administration of IDOV-SAFE

Advanced Malignant Solid Tumor of Digestive System

China
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC; Seagen Inc.

Recruiting

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Locally Advanced or Metastatic Malignant Solid Tumors

United States, Japan, Canada
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Chemotherapy-Induced Peripheral Neuropathy

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Completed

Whole Body Vibration for the Improvement of Health and Functioning in Participants With Chemotherapy-Induced Peripheral Neuropathy

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Chemotherapy-Induced Peripheral Neuropathy

United States
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Completed

PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy

Malignant Solid Tumors
Daiichi Sankyo, Inc.

Completed

Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors

Advanced Solid Malignant Tumors | Advanced Ovarian Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
BeiGene

Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Breast Cancer | Metastatic Breast Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Hormone Receptor Positive Malignant Neoplasm of Breast | HER2-negative Breast Cancer | Hormone-receptor-positive Breast Cancer

China
Chinese PLA General Hospital

Recruiting

Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells

Solid Tumor | Hematological Malignancy

China
Kartos Therapeutics, Inc.
GlaxoSmithKline

Completed

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

Melanoma | Cancer | Advanced Solid Tumors | Oncology | Tumors | Advanced Malignancy | Oncology Patients

United States, Australia
National Cancer Institute (NCI)

Active, not recruiting

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Radiosurgery Before Surgery for the Treatment of Brain Metastases

Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Brain

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
University of Southern California
National Cancer Institute (NCI); Auransa, Inc.

Recruiting

AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Advanced Hepatocellular Carcinoma | Metastatic Malignant Neoplasm in the Liver | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Advanced Cholangiocarcinoma

United States
Ikena Oncology

Recruiting

Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors

Solid Tumor | Solid Tumors, Adult | Malignant Pleural Mesothelioma (MPM) | Epithelioid Hemangioendothelioma (EHE) | NF2 Deficient Mesothelioma | Other NF2 Deficient Solid Tumors and Solid Tumors With YAP1/TAZ Fusion Genes | NF2 Deficiency | YAP1 or TAZ Gene Fusions

United States, United Kingdom
National Cancer Institute (NCI)

Enrolling by invitation

Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment

Melanoma | Pancreatic Cancer | Lung Cancer | Solid Tumors | Gastrointestinal Cancer | Hematologic Malignancy | Liver Cancer | Pre-Malignancy

United States
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies

Solid Tumor | Gynecological Malignant Tumor

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Chemotherapy-Induced Peripheral Neuropathy

United States
M.D. Anderson Cancer Center

Recruiting

Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

Malignant Solid Neoplasm | Carcinoma In Situ | Hematopoietic and Lymphatic System Neoplasm

United States, Canada
EpicentRx, Inc.

Completed

A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab (PRIMETIME)

Lymphoma | Malignant Solid Tumor

United States
Memorial Sloan Kettering Cancer Center
Samus Therapeutics

Active, not recruiting

PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study

Non-Hodgkin's Lymphoma | Myeloma | Active Solid Malignancy

United States
Eli Lilly and Company

Completed

A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma

Lymphoma, Malignant | Solid Tumor

China
Eli Lilly and Company

Completed

A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin

Lymphoma, Malignant | Solid Tumor

France
Seoul National University Hospital
GC Biopharma Corp

Completed

Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor (MG4101)

Solid Tumors | Malignant Lymphomas

Korea, Republic of
Emory University
National Cancer Institute (NCI)

Not yet recruiting

Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases

Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Brain

United States

Clinical Trials on Solid Malignancy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations